Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 24, 2026Frontiers in Cardiovascular MedicineOpen Access

Effects of dapagliflozin on myocardial motion parameters and cardiac electrophysiology in patients with type 2 diabetes Mellitus and coronary heart disease

View Full Paper
Ask AI
Bookmark
Share

Key result

Dapagliflozin linked to improved longitudinal strain and cardiac electrophysiology in T2DM and CHD.

  • P<0.001
  • n=262

Why the study?

Does dapagliflozin improve myocardial motion parameters and cardiac electrophysiology in patients with type 2 diabetes mellitus and coronary heart disease?

Population

262 patients with type 2 diabetes mellitus and coronary heart disease admitted between January 2021 and…

Comparison

Dapagliflozin 10 mg daily added to standard CHD… vs Conventional treatment for 4 weeks

Design

Cohort

Follow-up

4 weeks

Authors

FLFang LiuRJRui Jin

Discussion

Loading...

Member takes

Overview

Supports adjunct dapagliflozin for cardiac parameters in T2DM-CHD; leaves open causal confirmation in randomized trials.

Key Points

  • This study aims to evaluate the effects of dapagliflozin on cardiac function and electrophysiological activity in patients with type 2 diabetes and coronary heart disease.
  • Retrospective study including 262 patients with type 2 diabetes and coronary heart disease.
  • Patients were assigned to either conventional treatment (137) or dapagliflozin plus conventional treatment (125) for 4 weeks.
  • Assessments included echocardiographic indices, myocardial motion parameters, cardiac electrophysiology, and exercise tolerance.
  • Dapagliflozin group showed superior clinical efficacy (93.60% vs. 76.64%, P < 0.001).
  • Improvements in left ventricular ejection fraction and myocardial motion metrics (P < 0.01).
  • Enhanced cardiac electrophysiological activity, with longer QT and Tp-Te intervals (P < 0.01).

Study Design

Type

Cohort (n=262)

Multicenter

No

Structured PICO

Does dapagliflozin improve myocardial motion parameters and cardiac electrophysiology in patients with type 2 diabetes mellitus and coronary heart disease?

P
Population
262 patients with type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD) admitted between January 2021 and January 2025
I
Intervention
Dapagliflozin 10 mg daily added to standard CHD therapy and metformin for 4 weeks
C
Comparator
Conventional treatment (standard CHD therapy plus metformin) for 4 weeks
O
Outcome
Clinical efficacy, echocardiographic cardiac function, myocardial motion parameters, left ventricular pressure-strain loop (LV-PSL) indices, electrophysiological activity, exercise tolerance, and adverse cardiovascular events at 4 weekssurrogate

Main Result

Absolute Event Rate: 26.59% vs 23.68%

p-value: p=<0.001

Adding dapagliflozin to conventional therapy for 4 weeks in patients with T2DM and CHD significantly improves cardiac function, myocardial performance, and electrophysiological parameters without increasing adverse events.

Limitations

  • Retrospective, single-center study design
  • Potential for unmeasured confounders
  • Short duration of intervention (4 weeks) limits assessment of long-term outcomes
  • Formal effect size calculations were not performed

Cite This Study

Liu et al. (2026) conducted a cohort in Type 2 diabetes mellitus and coronary heart disease (n=262). Dapagliflozin vs. Conventional treatment (standard CHD therapy plus metformin) was evaluated on Longitudinal pre-stretch peak strain (LPSS) at 4 weeks (p=<0.001). Dapagliflozin added to conventional therapy significantly improved longitudinal pre-stretch peak strain (26.59% vs. 23.68%, p<0.001) and cardiac electrophysiology in patients with T2DM and CHD.

synapsesocial.com/papers/6a3c2356d15afadd906fa02bhttps://doi.org/10.3389/fcvm.2026.1745362
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of dapagliflozin on blood glucose control, cardiac function, and myocardial injury markers in patients with type 2 diabetes and heart failure2024
  2. 2Effects of dapagliflozin on the progression of left ventricular dysfunction in type 2 diabetes mellitus: a randomized controlled trial2025 · 6 citations
  3. 3Effect of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on ventricular repolarization electrocardiographic parameters in type 2 diabetes patients: DAPA - ECG study2025 · 1 citations
  4. 4The effect of dapagliflozin on cardiorespiratory fitness in patients with coronary heart disease and type 2 diabetes mellitus following PCI: a single-center prospective randomized controlled study2026 · 1 citations
  5. 5Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes With Established Ischemic Heart Disease (EDIFIED)2019 · 55 citations